言語を選択

Integrin alpha 4 beta 1

Integrin alpha 4 beta 1 詳細

英語名	Integrin alpha-4/beta-1	市販薬剤の数	3
治験薬の数	6	ターゲットの別称	Integrin alpha4beta1
研究＆開発段階	Approved

英語名	Integrin alpha-4/beta-1
ターゲットの別称	Integrin alpha4beta1
市販薬剤の数	3
治験薬の数	6
研究＆開発段階	Approved

Integrin alpha 4 beta 1 製品リスト

属性
Protein (2)
製品ライブラリ
オンライン (2)
種
Human (2)
タグ
His Tag (1)His Tag & Avi Tag (1)
マーカー
Unconjugated (1)Biotin-labeled (1)

製品番号	種	発現システム	製品説明	タンパク質の構造	純度	特性
IT1-H52W1	Human	HEK293	Human Integrin alpha 4 beta 1 (ITGA4&ITGB1) Heterodimer Protein, His Tag&Tag Free, low endotoxin
IT1-H82W1	Human	HEK293	Biotinylated Human Integrin alpha 4 beta 1 (ITGA4&ITGB1) Heterodimer Protein, His,Avitag™&Tag Free

総数量2

Integrin alpha 4 beta 1バックグランド

Integrins are transmembrane proteins that mediate interactions between adhesion molecules on adjacent cells and/or the extracellular matrix (ECM). Integrins have diverse roles in several biological processes including cell migration during development and wound healing, cell differentiation, and apoptosis. Their activities can also regulate the metastatic and invasive potential of tumor cells. Integrin alpha 4 beta 1(Alpha-4/beta-1) is receptors for fibronectin. Integrin alpha-4/beta-1 is a receptor for VCAM1 and recognizes the sequence Q-I-D-S in VCAM1.

Integrin alpha 4 beta 1分子の別称

Integrin alpha 4 beta 1,ITGA4&ITGB1

治験薬に関する情報

英語名	研究コード	研究開発ステージ	会社	適応症	臨床試験
Natalizumab biosimilar (GENERIUM Pharmaceuticals)	GNR-093	Phase 3 Clinical	Generium Pharmaceuticals	Multiple Sclerosis	詳細
Avicursen	TV-1102; ATL/TV-1102; ATL-1102; ISIS-107248	Phase 2 Clinical	Ionis Pharmaceuticals Inc	Multiple Sclerosis; Muscular Dystrophy, Duchenne	詳細
Alintegimod	7HP349; 7-HP-349; 7HP-349	Phase 2 Clinical	7 Hills Pharma LLC	Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Chagas Disease; Colorectal Neoplasms; Coronavirus Disease 2019 (COVID-19); Influenza, Human; Kidney Neoplasms; Lymphoma; Melanoma; Mesothelioma; Mismatch Repair Deficient Cancer; Neoplasm Metastasis; Neoplasms; Skin Neoplasms; Solid tumours; Tuberculosis	詳細
LLP2A alendronate		Phase 1 Clinical	University Of California	Bone Diseases; Bone Diseases, Metabolic; Osteonecrosis; Osteoporosis	詳細
ABBV-243	ABBV-243	Phase 1 Clinical	Abbvie Inc		詳細
RBx-7796	RBx-7796	Clinical	Sun Pharmaceutical Industries Ltd	Asthma; Rhinitis, Allergic	詳細

市販薬剤に関する情報

英語名	研究コード	研究開発ステージ	会社	オリジナル製品名	最初に承認をした国	最初の適応症	最初に承認を受けた会社	承認された日付	適応症	臨床試験
Carotegrast methyl	AJM-300	Approved	Ea Pharma, Eisai Co Ltd	Carogra	Japan	Colitis, Ulcerative	Ea Pharma Co Ltd	2022-03-28	Colitis, Ulcerative	詳細
Natalizumab biosimilar (Polpharma Biologics)	PB-006; DST-356A1	Approved	Polpharma Biologics Sa	Tyruko	United States	Multiple Sclerosis; Crohn Disease	Sandoz Inc	2023-08-24	Crohn Disease; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting	詳細
Natalizumab	BG-0002; TY-21.6; AN-10022; BG-00002; AN-100226; BG-0002-E	Approved	Biogen Inc, Perrigo Llc	Tysabri, Antegran, Antegren	United States	Crohn Disease; Multiple Sclerosis	Biogen Idec	2004-11-23	Arthritis, Rheumatoid; Crohn Disease; Demyelinating Diseases; Epilepsies, Partial; Graft vs Host Disease; Ischemic Stroke; Multiple Myeloma; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Myositis, Inclusion Body	詳細